Dana IncorporatedNYSE: DAN

THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) announced today the appointment of Dana Hamilton to the company's Board of Directors. Ms. Hamilton is a veteran C-suite executive with a track record of growing successful real estate operating and investment companies and using data analytics and technology to drive performance-enhancing organizational and industry change.

Dana Incorporated's share price has underperformed the broader market, but the company's revenue and cash flows have been generally positive. The company's revenue increased by 3.9% in the last fiscal year, driven by organic growth in Europe and light truck and medium/heavy truck production. Despite some weaknesses in profitability, management remains optimistic about the company's future and expects revenue and EBITDA to increase in the next fiscal year.

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.

While the revenue and EPS for Dana (DAN) offer insight into its performance in the first quarter of 2024, it is important to also analyze how certain key metrics stack up against Wall Street predictions and the previous year's figures.

Dana (DAN) reported earnings of $0.02 per share for the quarter, falling short of the Zacks Consensus Estimate of $0.10 per share. This is lower than the earnings of $0.25 per share reported in the same quarter last year.

The headline numbers for Dana (DAN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Dana (DAN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.10 per share a year ago.

Dana (DAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dana (DAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.